Conference Correspondent

Dose-Ranging Phase 2 Results of Nivolumab Therapy in Metastatic Renal-Cell Carcinoma

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Pembrolizumab in the Treatment of Patients with Advanced Urothelial Tract Cancer

ESMO 2014 - Immuno-Oncology, ESMO

Conference Correspondent — September 30, 2014

Interim Analysis of BATON-CRC: Tivozanib plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer

ESMO 2014 - Gastrointestinal and Head & Neck Cancer, ESMO

Conference Correspondent — September 29, 2014

Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 29, 2014

Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 29, 2014

Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 29, 2014

Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 29, 2014

Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 29, 2014

Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance

ESMO 2014 - Prostate Cancer, ESMO

Conference Correspondent — September 29, 2014

Impact of p16 Status on Cetuximab + Radiotherapy in Locally Advanced SCCHN

ASCO, ASCO 2014 – Colorectal and Head & Neck Cancer

Conference Correspondent — June 3, 2014

This was a retrospective analysis of the phase 3 IMCL-9815 trial assessing the role of HPV-p16 status in patients with locally advanced SCCHN receiving radiation therapy (RT) plus cetuximab (cetux) or RT alone (Rosenthal DI, et al. ASCO 2014. Abstract 6001).

Page 37 of 44

34
35
36
37
38
39
40